Agilvax discovers and develops targeted cancer immunotherapies using its proprietary discovery and development technology. **Agilvax's** lead product, **AX09**, is being developed for the treatment of triple-negative breast cancer (TNBC) by inhibiting the function of **xCT**, a novel molecular mechanism responsible for tumor growth and metastatic progression.

TNBC Unmet Need

TNBC is the most aggressive form of breast cancer with a 5-year survival rate of 26.1% for Stage IV patients and chemotherapy remains the standard of care. With an incidence rate ranging from 12.2% in the U.S. to 22.4% in China, there are approximately 300,000 global cases of TNBC diagnosed each year. The need for effective systemic therapies is an absolute clinical imperative.

Target xCT

xCT has known metabolic functions in normal and cancer cells playing a critical role in cellular defenses, detoxification, and intracellular balance. **xCT** overexpression occurs in several cancers leading to overarching metabolic changes that reprograms cells for tumor growth and survival. **xCT** overexpression has also been shown in non-small cell lung cancer, pancreatic, gastrointestinal, glioblastoma and colorectal cancers providing several opportunities for market growth and expanded indications of **AX09**.



Lead Product AX09

AX09 is an innovative immunotherapeutic agent that displays a specific antigen of **xCT** that elicits a significant anti-xCT immune response. In preclinical breast cancer models AX09 impaired tumor growth and reduced metastatic progression with no observed toxicity. Agilvax has also demonstrated that combination with chemotherapy strongly enhanced the anti-metastatic and anti-tumor potential of the individual treatments.

Target Market

According to GlobalData, the worldwide TNBC drug market is projected to grow at annual rate of 11.2% reaching $2.1 billion by 2025 with the U.S. representing 56% market share. Agilvax's regulatory strategy is to target 2nd line and later treatment segments for metastatic TNBC in combination with chemotherapy and/or checkpoint inhibitors. Label expansion into adjuvant use and earlier treatment lines to follow.

Milestones

- Awarded $2.3 million Fast-Track SBIR grant (2018). The grant funding will be utilized to complete the preclinical activities including efficacy of **AX09**, cGMP production and GLP toxicology.
- Recently opened a facility at **JLABS** at the Texas Medical Center in Houston, Texas where essential preclinical studies of **AX09** will occur to further demonstrate efficacy and safety
- Three scientific peer reviewed publications specifically related to **AX09** and **xCT** inhibition in preclinical models of efficacy and safety.
- Eight issued U.S. and international patents and several pending applications for Agilvax technology

Financing

- Initiated a Series B capital raise targeting $15 million to complete a Phase I/IIa clinical study.
- Raised $5.5 million in equity capital to date and recently closed A1 round.
- Financing strategy is to supplement the capital raise by pursuing non-dilutive options such as government grants and strategic partnerships.

MANAGEMENT

Federica Pericle, PhD, MBA
President and CEO

Les Stewart, MBA
Chief Operating Officer

Michael Perrine, MS, MBA
Haifa Hamdi, PhD
Jerri Caldeira, PhD

BOARD

Ebetuel (Beto) Pallares, PhD
Joseph Advisory Services/ Hunt Holdings

Waneta Tuttle, PhD, MBA
CEO Southwest Medical Ventures

Federica Pericle, PhD, MBA
President and CEO

Brad H. Vale, PhD, DVM
CEO of Calaveras Creek Capital and former Head of Johnson & Johnson Development Corp

Faith L. Charles, JD
Partner in Thompson Hine's Corp. Transactions & Securities

Brian Birk
Managing Partner of Sun Mountain Capital

Stuart Rose, PhD
Founder of The Bioscience Center and FatPipe ABQ

ADVISORY TEAM

George Peoples, MD,
Cancer Insight

Enrico Braglia
OneLife, Helsinn

Federica Cavallo , PhD
Associate Professor, University of Turin

Bryce Chackerian, PhD
Associate Professor, University of New Mexico

David Peabody, PhD
Associate Professor, University of New Mexico

Naoto Ueno, MD, PhD
MD Anderson Cancer Center

Saira Ramasastry
Life Sciences Advisory, LLC

Karthik Radhakrishnan
Titania Partners LLC

Agilvax, Inc. CEO contact: fpericle@agilvax.com / www.agilvax.com

HEADQUARTERS
5901 Indian School Rd NE
Albuquerque, NM 87110

JLABS@TMC
2450 Holcombe Blvd Suit J,
Houston, TX 77021

Wells Fargo Plaza
221 N. Kansas, Ste 504
El Paso, TX 79901